BioSpace News Archive

Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series, throughout the month of April.

IQVIA Acquires Remaining Interest in Q 2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension – Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo –

Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks

Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications:

-- New sponsored testing program can make it easier for patients to receive genetic testing in Parkinson’s disease, early-onset Alzheimer’s disease, ALS and other common conditions --

Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with R ecessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB)

Broncus Medical , Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced publication of results from the VAPORIZE study in the current issue of Respiration. The feasibility study reported on the use of bronchoscopic thermal vapor ablation (BTVA) in ablating lung tumors.

StageZero Life Sciences, Ltd is pleased to announce that effective March 31, 2021 is has entered into a letter of intent to purchase substantially all of the business of Health Clinics Limited and of Health Clinics USA Corp.